Decisions about gene‑editing and novel therapies are being made with inadequate involvement from Deaf people who use sign language, a senior figure at the British Deaf Association has warned. In a letter responding to a recent editorial on human gene editing, the organisation’s head of policy and research said vital debate and information are not routinely available in signed languages, risking exclusion from conversations that will shape future health policy.
Concern follows wider public discussion on gene editing
The letter responds to commentary urging a national conversation about the future of gene‑editing — including its medical potential and the darker applications that worry ethicists. Polling cited in that discussion suggests the UK public broadly supports corrective uses of gene editing for life‑threatening genetic conditions, while showing far less support for altering traits that are not life‑threatening, such as deafness.
International developments highlight the immediacy
One trigger for the letter was a recent move in the United States where the Food and Drug Administration approved a specific gene therapy for deafness. The FDA described its action as “acting swiftly” after the underlying research appeared in the New England Journal of Medicine. The British Deaf Association warns that such regulatory and scientific conversations — and the media coverage that follows — are rarely, if ever, provided in signed languages.
"Nothing about us without us"
The letter invoked that familiar principle to stress that decisions affecting Deaf people should not be taken without their informed participation. The author, identified as Tom Lichy, head of policy and research at the British Deaf Association, urged UK policymakers to ensure accessibility is a consistent feature of public engagement on gene therapies.
What is at stake
At its core, the concern combines three elements:
- Access to information — technical and policy discussions are not being routinely provided in signed language;
- Informed consent and public dialogue — without accessible discussion, Deaf sign‑language users cannot participate fully in shaping policy;
- Equity in healthcare decisions — therapies targeting traits such as deafness raise cultural and ethical questions that directly affect the Deaf community.
These points underline both democratic and ethical implications for how the UK approaches future consultations on gene editing and new therapies.
| Stakeholder | Main concern |
|---|---|
| Deaf sign‑language users | Access to explanations and debate in signed languages |
| Policymakers | Ensuring inclusive consultation practices |
| Medical/regulatory bodies | Communicating approvals and evidence accessibly |
The letter calls on UK authorities to incorporate signed‑language provision into public engagement on gene editing — not as an optional extra but as a routine element of policy development. As gene therapies move from research to regulatory decisions, the British Deaf Association’s warning is a prompt to reconsider how inclusivity is planned into national conversations about science and health.
